SEOUL, April 11 (Korea Bizwire) — South Korean pharmaceutical firm Yuhan Corp. said Monday its degenerative disc drug licensed out to an American drug company will go on Phase 3 clinical trial in the United States. U.S.-based Spine BioPharma has been given permission from the U.S. Food and Drug Administration to bypass the second phase [...]
SEOUL, Feb. 21 (Korea Bizwire) – Yuhan Corporation, GC Pharma, and Kwang Dong Pharmaceutical are expected to hold the top three positions in the South Korean pharmaceutical industry this year, with their latest sales figures exceeding 1 trillion won. Both Yuhan and GC Pharma are on course to join the ‘one trillion club’ again this year, [...]
SEOUL, Nov. 17 (Korea Bizwire) – South Korea’s big three pharmaceutical ranking chart is expected to change this year as sales of Chong Kun Dang Pharmaceutical Corp. in the first three quarters beat those of Hanmi Pharmaceutical Co., the previous No. 3, their regulatory filings showed Thursday. Yuhan Co. held its leading position with 964.4 [...]
SEOUL, Oct. 31 (Korea Bizwire) – Domestic pharmaceutical firms have started to release sensitive information that may play to their disadvantage, mainly in order to eliminate any misunderstanding or speculation by not disclosing information in advance. The move is also driven by the recent Hanmi Pharmaceutical controversy, in which the company allegedly leaked insider information [...]
SEOUL, Nov. 5 (Korea Bizwire) – Yuhan Corporation, the first runner in terms of sales and net profit among Korean drug companies, is expected to reach one trillion won sales this year, for the first time as a pharmaceutical company. In a recent electronic disclosure to the Financial Supervisory Service, Yuhan said that its preliminary [...]